Deutsche Bank AG Boosts Holdings in Fulgent Genetics, Inc. $FLGT

Deutsche Bank AG lifted its position in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT - Free Report) by 105.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 269,770 shares of the company's stock after buying an additional 138,340 shares during the quarter. Deutsche Bank AG owned about 0.87% of Fulgent Genetics worth $4,559,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of FLGT. Millennium Management LLC increased its position in shares of Fulgent Genetics by 20.6% during the fourth quarter. Millennium Management LLC now owns 1,531,801 shares of the company's stock worth $28,292,000 after buying an additional 261,152 shares during the period. Ameriprise Financial Inc. boosted its stake in Fulgent Genetics by 40.8% during the fourth quarter. Ameriprise Financial Inc. now owns 501,809 shares of the company's stock worth $9,268,000 after acquiring an additional 145,518 shares in the last quarter. GSA Capital Partners LLP boosted its stake in Fulgent Genetics by 442.1% during the first quarter. GSA Capital Partners LLP now owns 104,815 shares of the company's stock worth $1,771,000 after acquiring an additional 85,481 shares in the last quarter. D. E. Shaw & Co. Inc. boosted its stake in Fulgent Genetics by 129.9% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 130,684 shares of the company's stock worth $2,414,000 after acquiring an additional 73,843 shares in the last quarter. Finally, GAMMA Investing LLC boosted its stake in Fulgent Genetics by 3,387.8% during the first quarter. GAMMA Investing LLC now owns 74,394 shares of the company's stock worth $1,257,000 after acquiring an additional 72,261 shares in the last quarter. 48.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Fulgent Genetics

In related news, COO Jian Xie sold 1,873 shares of the firm's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $20.54, for a total transaction of $38,471.42. Following the transaction, the chief operating officer directly owned 372,631 shares of the company's stock, valued at $7,653,840.74. This trade represents a 0.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 31.76% of the stock is owned by insiders.

Fulgent Genetics Stock Performance

Shares of Fulgent Genetics stock traded up $0.6250 during trading hours on Friday, reaching $22.0250. The company's stock had a trading volume of 47,004 shares, compared to its average volume of 353,931. Fulgent Genetics, Inc. has a one year low of $14.57 and a one year high of $23.99. The company has a market capitalization of $674.19 million, a P/E ratio of -13.24 and a beta of 0.83. The stock's fifty day simple moving average is $19.63 and its two-hundred day simple moving average is $18.71.

Fulgent Genetics (NASDAQ:FLGT - Get Free Report) last released its quarterly earnings data on Friday, August 1st. The company reported $0.07 earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.30. Fulgent Genetics had a negative net margin of 16.83% and a negative return on equity of 2.26%. The firm had revenue of $81.80 million for the quarter, compared to analyst estimates of $76.21 million. During the same period last year, the firm earned $0.15 earnings per share. The business's quarterly revenue was up 15.2% compared to the same quarter last year. Fulgent Genetics has set its FY 2025 guidance at -0.350--0.350 EPS. As a group, research analysts forecast that Fulgent Genetics, Inc. will post -0.85 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on FLGT shares. UBS Group raised shares of Fulgent Genetics from a "neutral" rating to a "buy" rating and increased their target price for the stock from $20.00 to $30.00 in a research note on Tuesday, August 5th. Raymond James Financial reissued an "outperform" rating and set a $25.00 target price (up from $24.00) on shares of Fulgent Genetics in a research note on Monday, May 5th. Finally, Piper Sandler set a $21.00 target price on shares of Fulgent Genetics and gave the stock a "neutral" rating in a research note on Monday, August 4th. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $25.33.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.